Compare DAKT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | STTK |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 963.2M | 792.9M |
| IPO Year | 1996 | 2020 |
| Metric | DAKT | STTK |
|---|---|---|
| Price | $17.98 | $6.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 720.4K | ★ 817.3K |
| Earning Date | 03-04-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 538.10 | 53.02 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $608,932,000.00 | $1,000,000.00 |
| Revenue This Year | $12.06 | N/A |
| Revenue Next Year | $9.16 | N/A |
| P/E Ratio | $44.15 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $17.09 | $1.70 |
| 52 Week High | $28.27 | $8.33 |
| Indicator | DAKT | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 34.92 | 42.18 |
| Support Level | N/A | $5.87 |
| Resistance Level | $20.80 | $7.75 |
| Average True Range (ATR) | 0.76 | 0.30 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 12.17 | 32.33 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.